

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

U 015119-4

NF/61/03




Fig 1: Role of Angiotensin Converting Enzyme in RAAS and KKP

U 015119-4

NF/61/03




Fig 3: Proposed interactions of designed peptidomimics with the active site of Angiotensin - converting enzyme

U 015119-4




Figure 4 : Lineweaverburk plot for L-Abrine-Ornithine-Proline. IC₅₀ of L-Abrine-Ornithine-Proline was found to be 10 μ M.

U 015119-4




Figure 5: Tail systolic pressure (TSP) in experimental and control group. Increments in TSP values for methylprednisolone induced experimental group was significantly different after 1st week ($p < 0.05$) and 2nd week ($p < 0.05$)

U 015119-4




Figure 6: Variation in blood pressure measured during i.v. administration of L-Abrine-Ornithine-Proline at doses of 5 mg/kg, 8 mg/kg and 10 mg/kg. Fall of blood pressure at all doses was significant ($p < 0.05$).